Find a lawyer
Let’s connect
Intellectual Property associate Jeffrey Coleman co-authored a Law360 article titled “Exploring The Amgen Genus Claims Headed To High Court” on Jan. 10, 2023. The article reviews whether generic claims in the chemical and biological arts are alive and well as the U.S. Court of Appeals for the Federal Circuit has explained in its 2021 Amgen Inc. v. Sanofi decision, as well as the hurdles faced by claiming biological materials by desired function rather than a structure shared by the biological materials.
Legal Notice
The contents of this publication are for reference purposes only and may not be current as at the date of accessing this publication. They do not constitute legal advice and should not be relied upon as such. Specific legal advice about your specific circumstances should always be sought separately before taking any action based on this publication.
© Herbert Smith Freehills Kramer 2026
Stay in the know
Receive timely insights and briefings from HSF Kramer, tailored to keep you informed and ahead
Subscribe now